| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Mal-GGG-Bal-NHS ester targets the conjugation of cytotoxic agents or payloads to antibodies in ADC synthesis. As an ADC linker, it does not have a direct biological target but serves as a chemical tool for drug delivery and biomolecule labeling. The NHS ester group enables efficient conjugation to primary amines on proteins or peptides. It is used in the synthesis of targeted therapeutics and ADC development.
|
|---|---|
| ln Vitro |
In vitro activity of Mal-GGG-Bal-NHS ester is demonstrated by its function as an ADC linker in the synthesis of antibody-drug conjugates. It facilitates the conjugation of cytotoxic agents to antibodies. The resulting ADCs are evaluated for their ability to bind to target antigens and deliver cytotoxic payloads. The linker's stability and release properties are critical for ADC activity.
|
| ln Vivo |
In vivo activity of Mal-GGG-Bal-NHS ester is not directly applicable, as the compound is a linker used in ADC synthesis rather than a therapeutic agent itself. The activity of ADCs synthesized using this linker would be evaluated in vivo. These ADCs are designed for targeted delivery of cytotoxic agents to cancer cells.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding assay for Mal-GGG-Bal-NHS ester is not applicable, as the compound is a chemical linker rather than a pharmacologically active agent. The synthesis and characterization of ADCs using this linker involve chemical conjugation reactions. The purity and functionality of the linker are assessed using analytical chemistry methods such as HPLC and mass spectrometry.
|
| Cell Assay |
In vitro cell-based assays for Mal-GGG-Bal-NHS ester are not directly applicable, as the compound is a linker used in ADC synthesis. ADCs synthesized using this linker would be evaluated in cell-based assays to assess binding affinity to target antigens, internalization, and cytotoxicity against cancer cell lines. Standard protocols include antigen binding assays, flow cytometry, and cell viability assays.
|
| Animal Protocol |
In vivo animal studies for Mal-GGG-Bal-NHS ester are not directly applicable, as the compound is a linker used in ADC synthesis. ADCs synthesized using this linker would be evaluated in xenograft mouse models to assess tumor growth inhibition, pharmacokinetics, and toxicity. Standard protocols include administration of the ADC, monitoring of tumor volume, and assessment of body weight and clinical signs.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Mal-GGG-Bal-NHS ester include a molecular weight of 522.47 and a molecular formula of C21H26N6O10. Solubility includes H2O: 50 mg/mL (ultrasonic). As an ADC linker, its pharmacokinetic properties would be determined by the final ADC conjugate. Detailed pharmacokinetic data are not available from the search results.
|
| Toxicity/Toxicokinetics |
Toxicity information for Mal-GGG-Bal-NHS ester is limited. As a research-use chemical, standard safety precautions for handling should be followed. The compound is designated for research use only and is not for human therapeutic applications. No specific toxicity data are available from the search results.
|
| References | |
| Additional Infomation |
Mal-GGG-Bal-NHS ester is an ADC linker that facilitates the synthesis of antibody-drug conjugates (ADCs). It contains an NHS ester group that enables efficient conjugation to peptides, proteins, or other biomolecules. It is used in targeted therapeutics, ADC development, and biomolecule-labeling applications. It has a molecular formula of C21H26N6O10 and a molecular weight of 522.47.
|
| Exact Mass |
522.171
|
|---|---|
| CAS # |
1193111-65-7
|
| PubChem CID |
57945503
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
37
|
| Complexity |
989
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CC(=O)N(C1=O)OC(=O)CCNC(=O)CNC(=O)CNC(=O)CNC(=O)CCCN2C(=O)C=CC2=O
|
| InChi Key |
NFJWAGOKMMRHHY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H26N6O10/c28-13(2-1-9-26-17(32)3-4-18(26)33)23-11-15(30)25-12-16(31)24-10-14(29)22-8-7-21(36)37-27-19(34)5-6-20(27)35/h3-4H,1-2,5-12H2,(H,22,29)(H,23,28)(H,24,31)(H,25,30)
|
| Chemical Name |
(2,5-dioxopyrrolidin-1-yl) 3-[[2-[[2-[[2-[4-(2,5-dioxopyrrol-1-yl)butanoylamino]acetyl]amino]acetyl]amino]acetyl]amino]propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~50 mg/mL (~95.70 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
